Literature DB >> 20152760

Targeting the target: a step forward for the treatment of non-small-cell lung cancer.

Jean Yves Douillard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20152760     DOI： 10.1016/S1470-2045(09)70390-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.

Authors:  David P Carbone; Keyue Ding; Heinrich Roder; Julia Grigorieva; Joanna Roder; Ming-Sound Tsao; Lesley Seymour; Frances A Shepherd
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

2.  Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.

Authors:  Xuan Wu; Wenhua Liang; Xue Hou; Zhong Lin; Hongyun Zhao; Yan Huang; Wenfeng Fang; Yuanyuan Zhao; Jingxun Wu; Yunpeng Yang; Chong Xue; Zhihuang Hu; Jing Zhang; Jianwei Zhang; Yuxiang Ma; Ting Zhou; Tao Qin; Li Zhang
Journal:  Onco Targets Ther       Date:  2013-10-21       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.